Top Page
Senzime AB
(SEZI)
Senzime AB (SEZI) vs. iShares MSCI Sweden ETF (EWD)
Senzime AB Business Overview & Revenue Model
Senzime AB Earnings Call Summary
Senzime AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.63M | 58.48M | 35.75M | 14.03M | 10.98M | 9.34M |
| Gross Profit | 32.92M | 20.12M | 8.34M | -4.39M | -4.92M | -7.90M |
| EBITDA | -84.03M | -95.53M | -118.82M | -120.05M | -73.20M | -36.96M |
| Net Income | -126.40M | -118.73M | -134.15M | -132.70M | -82.14M | -47.45M |
Balance Sheet | ||||||
| Total Assets | 435.22M | 424.53M | 433.54M | 322.68M | 174.62M | 258.89M |
| Cash, Cash Equivalents and Short-Term Investments | 132.16M | 100.94M | 151.01M | 26.04M | 74.87M | 160.31M |
| Total Debt | 14.94M | 22.67M | 11.47M | 13.04M | 1.63M | 2.40M |
| Total Liabilities | 63.82M | 78.67M | 58.06M | 60.78M | 24.04M | 27.55M |
| Stockholders Equity | 371.40M | 345.86M | 375.48M | 261.90M | 150.58M | 231.35M |
Cash Flow | ||||||
| Free Cash Flow | -125.35M | -126.28M | -121.73M | -141.89M | -84.30M | -38.66M |
| Operating Cash Flow | -103.29M | -105.94M | -113.91M | -136.78M | -81.33M | -38.34M |
| Investing Cash Flow | -22.06M | -20.34M | -7.82M | -4.98M | -2.97M | -327.00K |
| Financing Cash Flow | 177.55M | 75.86M | 246.51M | 92.36M | -945.00K | 167.69M |
Senzime AB Technical Analysis
Senzime AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | €1.11B | 43.19 | 6.93% | ― | -5.80% | -65.99% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | kr1.44B | ― | ― | ― | 36.23% | 63.14% | |
| ― | $932.29M | -6.14 | -36.55% | ― | 62.24% | 21.16% | |
| ― | €1.05B | -25.90 | -4.42% | ― | 13.48% | 28.98% | |
| ― | kr615.02M | ― | -6.81% | ― | -8.10% | 62.08% | |
| ― | €183.05M | -5.61 | -18.35% | ― | -5.63% | -1373.99% |
Senzime AB Corporate Events
Senzime AB, a medical technology company, specializes in developing algorithm-based patient monitoring systems to prevent anesthesia-related complications. In its latest earnings report for Q3 2025, Senzime highlighted significant growth with net sales increasing by 52% compared to the previous year, driven by strong performance in the U.S. market and strategic deals. The company reported an improved EBITDA and a strengthened cash position, despite challenges from currency fluctuations and new U.S. tariffs. Key strategic moves included expanding its TetraGraph system’s market presence and launching new software, EMGINE™, to enhance patient monitoring capabilities. Looking ahead, Senzime remains focused on leveraging its technological advancements and strategic partnerships to drive further growth and profitability in the global market.
Senzime AB has launched EMGINE, a next-generation software suite for its TetraGraph® platform, aimed at advancing neuromuscular monitoring. This new technology, which will be showcased at the ANESTHESIOLOGY 2025 conference, is built on extensive real-world data and offers enhanced patient safety and compliance with international guidelines. The EMGINE software, featuring advanced algorithms and noise-reduction technology, is expected to strengthen Senzime’s position in the medical device industry by providing hospitals with state-of-the-art monitoring capabilities.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB has welcomed new European pediatric guidelines recommending EMG-based neuromuscular monitoring during anesthesia, a technology utilized by their TetraGraph system. This development is significant for pediatric patient safety and presents new market opportunities for Senzime, as their system is specifically designed for pediatric use and is already in use at leading hospitals.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB has secured a significant contract with the U.S. Department of Defense to supply its TetraGraph system to Walter Reed National Military Medical Center, marking a major commercial milestone. This partnership highlights Senzime’s commitment to patient safety and its strong market position, as the TetraGraph system is widely used in operating rooms globally to ensure accurate dosing of neuromuscular blocking agents, enhancing patient recovery post-surgery.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB announced its participation in the Pareto Securities’ 16th Annual Healthcare Conference, where CEO Philip Siberg will present the company’s advancements. This participation underscores Senzime’s commitment to engaging with industry professionals and investors, potentially enhancing its market presence and stakeholder relations.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB has announced the integration of its TetraGraph neuromuscular monitoring system with Mindray’s patient monitors, enhancing data connectivity and real-time patient data transfer. This integration strengthens Senzime’s competitive position by offering the broadest range of connectivity options in the industry, aligning with its strategy to make its technology a standard of care in hospitals worldwide.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB has announced that the Japanese Society of Anesthesiology has updated its clinical guidelines to require quantitative neuromuscular monitoring during anesthesia, which is expected to boost the adoption of Senzime’s TetraGraph system in Japan. With the new guidelines aligning with global trends and Senzime’s existing installations in Japanese hospitals, the company anticipates increased utilization of its monitoring systems, potentially improving patient outcomes and expanding its market presence in Japan.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB announced that its CEO, Philip Siberg, will present at the European Growth Virtual Investor Conference on September 11, 2025. This event provides an opportunity for investors to engage with the company in real-time, potentially impacting Senzime’s visibility and investor relations in the healthcare monitoring industry.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime AB announced that a major university hospital system in California has standardized on its TetraGraph system for neuromuscular monitoring, with an initial order of 35 systems to be used in operating rooms for over 10,000 surgeries annually. This strategic win enhances Senzime’s market position in the US, as hospitals seek to comply with guidelines and improve patient safety, while the TetraGraph system’s scalable business model continues to drive growth in a large, underpenetrated market.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
Senzime has achieved a significant milestone by securing the installation of its TetraGraph system across all sites of a top-ranked US hospital system. This expansion is expected to impact approximately 15,000 patients annually, reinforcing Senzime’s position in the market and aligning with clinical guidelines for neuromuscular monitoring. The TetraGraph system, developed through over 40 years of research, offers proprietary capabilities that enhance patient safety and compliance with clinical standards.